Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$26.86|
|52 Week High||US$22.00|
|52 Week Low||US$45.44|
|1 Month Change||15.18%|
|3 Month Change||-7.70%|
|1 Year Change||-19.05%|
|3 Year Change||23.61%|
|5 Year Change||79.07%|
|Change since IPO||-83.72%|
Recent News & Updates
Is Insmed (NASDAQ:INSM) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
|INSM||US Biotechs||US Market|
Return vs Industry: INSM underperformed the US Biotechs industry which returned 24.9% over the past year.
Return vs Market: INSM underperformed the US Market which returned 33.7% over the past year.
Stable Share Price: INSM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: INSM's weekly volatility (6%) has been stable over the past year.
About the Company
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders.
Insmed Fundamentals Summary
|INSM fundamental statistics|
Is INSM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|INSM income statement (TTM)|
|Cost of Revenue||US$132.84m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.60|
|Net Profit Margin||-219.67%|
How did INSM perform over the long term?See historical performance and comparison
Is Insmed undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INSM ($26.86) is trading below our estimate of fair value ($43.58)
Significantly Below Fair Value: INSM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: INSM is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: INSM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INSM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: INSM is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.2x).
How is Insmed forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INSM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INSM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INSM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INSM's revenue (40.3% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: INSM's revenue (40.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: INSM is forecast to be unprofitable in 3 years.
How has Insmed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INSM is currently unprofitable.
Growing Profit Margin: INSM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INSM is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.
Accelerating Growth: Unable to compare INSM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INSM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: INSM has a negative Return on Equity (-70.58%), as it is currently unprofitable.
How is Insmed's financial position?
Financial Position Analysis
Short Term Liabilities: INSM's short term assets ($1.0B) exceed its short term liabilities ($99.7M).
Long Term Liabilities: INSM's short term assets ($1.0B) exceed its long term liabilities ($599.1M).
Debt to Equity History and Analysis
Debt Level: INSM's debt to equity ratio (103.3%) is considered high.
Reducing Debt: INSM's debt to equity ratio has increased from 8.5% to 103.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INSM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if INSM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Insmed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INSM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INSM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INSM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INSM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INSM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Will Lewis (52 yo)
Mr. William H. Lewis, also known as Will, J.D., M.B.A., has been Chief Executive Officer and President at Insmed Incorporated since September 11, 2012 and has been its Chairman of Board since November 6, 2...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD6.19M) is about average for companies of similar size in the US market ($USD5.25M).
Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.
Experienced Management: INSM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: INSM's board of directors are considered experienced (3.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.6%.
Insmed Incorporated's employee growth, exchange listings and data sources
- Name: Insmed Incorporated
- Ticker: INSM
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.096b
- Shares outstanding: 115.25m
- Website: https://www.insmed.com
Number of Employees
- Insmed Incorporated
- 700 US Highway 202/206
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/16 22:48|
|End of Day Share Price||2021/09/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.